Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, Sancho JM, Ramírez MJ, Terol MJ, Capote FJ, Gutiérrez A, Sánchez B, López A, Salar A, Rodríguez-Caravaca G, Canales M, Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group).

Cancer Med. 2019 Oct 1. doi: 10.1002/cam4.2555. [Epub ahead of print]

2.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

3.

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO).

Haematologica. 2017 Feb;102(2):235-245. doi: 10.3324/haematol.2016.149120. Epub 2016 Oct 20.

4.

How to facilitate early diagnosis of CNS involvement in malignant lymphoma.

Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M.

Expert Rev Hematol. 2016 Nov;9(11):1081-1091. Epub 2016 Oct 21. Review.

PMID:
27677656
5.

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18.

PMID:
27188649
6.

Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.

Alvarez-Twose I, Martínez-Barranco P, Gotlib J, García-Montero A, Morgado JM, Jara-Acevedo M, Merker JD, Peñalver FJ, Matito A, Hou Y, Sánchez-Muñoz L, Mayado A, Mollejo M, Escribano L, Orfao A.

Leukemia. 2016 Aug;30(8):1753-6. doi: 10.1038/leu.2016.30. Epub 2016 Feb 15. No abstract available.

PMID:
26876592
7.

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J.

Leuk Res Rep. 2015 Sep 24;4(2):64-9. doi: 10.1016/j.lrr.2015.09.002. eCollection 2015.

8.

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9.

PMID:
26179864
9.

Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.

Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, García-Álvarez MF, Sánchez-González B, Peñalver FJ, Cannata J, Espeso M, Requena MJ, Gardella S, Durán S, González AP, Alfonso A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):398-403. doi: 10.1016/j.clml.2015.02.029. Epub 2015 Mar 5.

PMID:
25843416
10.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO).

Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19.

PMID:
27029228
11.

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF.

Blood. 2014 Sep 18;124(12):1887-93.

PMID:
25102853
12.

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.

Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A; Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma.

Blood. 2014 Mar 20;123(12):1864-9. doi: 10.1182/blood-2013-11-537993. Epub 2014 Feb 5.

PMID:
24501214
13.

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Polo M, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Lahuerta JJ, Bladé J, San-Miguel JF.

Blood. 2012 Sep 27;120(13):2581-8. Epub 2012 Aug 13.

PMID:
22889759
14.

Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.

Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.

Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024. Epub 2011 Dec 7.

PMID:
22154023
15.

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.

Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF.

Blood. 2011 Oct 27;118(17):4547-53. doi: 10.1182/blood-2011-04-345801. Epub 2011 Sep 6.

PMID:
21900193
16.

[Pure red cell aplasia and Hashimoto's thyroiditis: a rare association].

Aranda C, Pérez M, Herreros B, Peñalver FJ.

Med Clin (Barc). 2011 Oct 15;137(10):476-7. doi: 10.1016/j.medcli.2010.12.018. Epub 2011 Apr 5. Spanish. No abstract available.

PMID:
21470643
17.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.

Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.

PMID:
20739218
18.

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.

Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL.

Eur J Haematol. 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28.

PMID:
20528905
19.

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.

Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, Díaz-Mediavilla J, Bustelos R, Fernández-Aceñero MJ, Cabrera JR; Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA.

Ann Hematol. 2010 Nov;89(11):1073-80. doi: 10.1007/s00277-010-0997-y. Epub 2010 Jun 5.

PMID:
20526716
20.

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF.

Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006.

PMID:
19557622
21.

Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.

Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A; Spanish Group for the Study of CNS Disease in NHL.

J Clin Oncol. 2009 Mar 20;27(9):1462-9. doi: 10.1200/JCO.2008.17.7089. Epub 2009 Feb 17.

PMID:
19224854
22.

Rituximab for patients with idiopathic thrombocytopenic purpura.

Peñalver FJ, Cabrera JR.

Ann Intern Med. 2007 Aug 21;147(4):281; author reply 281-2. No abstract available.

PMID:
17709765
23.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.

Ann Hematol. 2006 Jun;85(6):400-6. Epub 2006 Mar 21. Erratum in: Ann Hematol. 2006 Aug;85(8):558. Dosage error in article text.

PMID:
16550390
24.

Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma.

Cabrera R, Díaz-Espada F, Barrios Y, Briz M, Forés R, Barbolla L, Sanjuán I, Regidor C, Peñalver FJ, Fernández MN.

Bone Marrow Transplant. 2000 May;25(10):1105-8.

25.

[Ischemic stroke as first manifestation of chronic myelogenous leukemia].

Benito-León J, Sánchez J, Osorio S, Peñalver FJ.

Rev Neurol. 1999 Aug 16-31;29(4):391-2. Spanish. No abstract available.

PMID:
10797937
26.

Mucormycosis and hemopoietic transplants.

Peñalver FJ, Romero R, Forés R, Cabrera R, Briz M, Fernández M.

Haematologica. 1998 Oct;83(10):950-1.

27.

Rhinocerebral mucormycosis following donor leukocyte infusion: successful treatment with liposomal amphotericin B and surgical debridement.

Peñalver FJ, Romero R, Forés R, Cabrera R, Díez-Martin JL, Regidor C, Fernández MN.

Bone Marrow Transplant. 1998 Oct;22(8):817-8.

28.

[The influence of a prior appointment on primary care consultations in the Murcia region].

Moreno E, Gómez-Calcerada D, Sandoval C, Cánovas J, Ramos C, Peñalver FJ, Guillén F, Marset P.

Aten Primaria. 1992 Jan;9(1):20-3. Spanish.

PMID:
1308444
29.

[Celiac disease, autoimmune cirrhosis, chronic pancreatitis: apropos of a triple association].

Faulques B, Grimaud JC, Leung PP, Bremondy A, Penalver F, Lebreuil G, Salducci J.

Gastroenterol Clin Biol. 1989 Dec;13(12):1082-5. French.

PMID:
2625189
30.

[Echographic diagnosis of intramural hematoma of the duodenum].

Bastid C, Penalver F, Sahel J, Sarles H.

Gastroenterol Clin Biol. 1986 Oct;10(10):694-5. French. No abstract available.

PMID:
3539690
31.

[Evaluation of protein catabolism in multi-injured patients].

François G, Bouffier C, Dumont JC, Penalver F.

Ann Fr Anesth Reanim. 1983;2(6):387-91. French.

PMID:
6660603

Supplemental Content

Loading ...
Support Center